180 related articles for article (PubMed ID: 32341708)
1. A Case Report on the Communication between Oncologists and Physiatrists in the Establishment of Functional Prognosis while Undergoing Chimeric Antigen Receptor T-cell Therapy.
Gupta E; Fu JB; Bruera E
J Med Life; 2020; 13(1):94-97. PubMed ID: 32341708
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
3. Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T; Johnson PC; Boateng K; Barata A; Traeger L; Nelson AM; Lavoie MW; Holmbeck K; Choe J; Nabily A; Tripathi A; Amonoo HL; Frigault M; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):402.e1-402.e12. PubMed ID: 38262530
[TBL] [Abstract][Full Text] [Related]
4. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
5. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release syndrome: grading, modeling, and new therapy.
Liu D; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):121. PubMed ID: 30249264
[TBL] [Abstract][Full Text] [Related]
7. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
Lee YH; Kim CH
Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
[TBL] [Abstract][Full Text] [Related]
8. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
12. Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review.
Hays P; Costello C; Asudani D
Future Oncol; 2019 Dec; 15(36):4235-4246. PubMed ID: 31773980
[TBL] [Abstract][Full Text] [Related]
13. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
Dudley CV; Baer B; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
16. The Cardiovascular Complications of Chimeric Antigen Receptor T Cell Therapy.
Jamal FA; Khaled SK
Curr Hematol Malig Rep; 2020 Apr; 15(2):130-132. PubMed ID: 32016789
[TBL] [Abstract][Full Text] [Related]
17. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome.
Pabst T; Joncourt R; Shumilov E; Heini A; Wiedemann G; Legros M; Seipel K; Schild C; Jalowiec K; Mansouri Taleghani B; Fux M; Novak U; Porret N; Zeerleder S; Bacher U
Exp Hematol; 2020 Aug; 88():7-14.e3. PubMed ID: 32673688
[TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
[Next] [New Search]